Author of

• 20156

  +

  P1.07 - Immunology and Immunotherapy (ID 693)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22698

    +

    P1.07-030 - Prognostic Impact of PD-L1 Expression in Correlation with HLA Class I Expression Status in Adenocarcinoma of the Lung (ID 9975)

    09:30 - 16:00  |  Presenting Author(s): Kazue Yoneda
    • Abstract

    Background:
    Programmed death-ligand 1 (PD-L1) and human leukocyte antigen (HLA) class I, expressed on tumor cells are important roles in cancer immunity. The current study was conducted to assess prognostic impact of PD-L1 status in correlation with HLA class I status in lung adenocarcinoma.
    
    Method:
    A total of 166 patients with completely resected lung adenocarcinoma were retrospectively reviewed. PD-L1 expression on tumor cells was evaluated with immunohistochemistry, in correlation with several clinicopathological and molecular features including HLA class I expression on tumor cells.
    
    Result:
    Twenty-one patients (12.7%) had tumor with positive PD-L1 expression (percentage of tumor cells expressing PD-L1, ≥ 5%), and the incidence was higher in smokers with higher smoking index and in poorly differentiated tumor. There was no significant correlation between HLA class I expression and PD-L1 expression. PD-L1 positivity provided no prognostic impact for all patients, but seemed to be correlated with a poor prognosis among patients with normal HLA class I expression (p=0.145). When only p-stage I patients were analyzed, PD-L1 positivity was a significant factor to predict a poor survival (5-year survival rate, 66.7% versus 85.9%; P=0.049), which was enhanced in tumor with normal HLA class-I expression (P=0.029) but was not evident in tumor with reduced HLA class I expression (P=0.552)
    
    Conclusion:
    The prognostic impact of PD-L1 expression on tumor cells in resectable lung adenocarcinoma was distinct according to HLA class I expression on tumor cells.